Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri

Recent developments in imaging technology, radiotherapeutic approaches, biological target therapy, and increased use of minimally invasive surgery have drastically changed the paradigm for management of women with cervical cancer.Until now, the International Federation of Gynecology and Obstetrics (FIGO) staging system was based primarily on clinical examination with limited additional diagnostic procedures allowed by the FIGO staging system.In 2018, the prior 2014 FIGO staging system was revised to incorporate imaging and pathological findings, when available, into the new staging system (Table 1) [1].Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri are discussed by gynecologic oncologists, radiation oncologists, radiologists, pathologists, and epidemiologists in this manuscript (Table 2). GYNECOLOGIC ONCOLOGISTS' PERSPECTIVES: FOR WHOM THIS PLATFORM IS?One of the major changes from the prior FIGO staging system is that the updated staging system now includes 3 subgroups for stage IB disease rather than 2. In the former system, stage IB disease was defined as (1) clinically and macroscopically visible lesions limited to the uterine cervix, or (2) microscopic lesions greater in size than stage IA disease.Tumors measuring less than or equal to 4 cm were classified as stage IB1, while those greater than